Risperidone in the treatment of Tourette syndrome: a retrospective case note study.
Nineteen patients with Tourette syndrome (TS) were treated with risperidone, at a mean daily dose of 1.5 mg. Of those, 41% responded positively, 35% felt that it had made no difference, while it made 24% worse. Although 53% of the patients experienced side-effects, none had extrapyramidal side-effects. At follow-up, 8 to 11 months later, only two of 19 (11 %) patients were still taking risperidone. We suggest that risperidone does have a role in a minority of TS sufferers but it is not suggested as the first line treatment. More placebo-controlled studies using risperidone are clearly indicated.
University College London Medical School, Middlesex Hospital Site, Mortimer Street, London W1N8AA, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG.
M M
MM
Robertson
D A
DA
Scull
V
V
Eapen
M R
MR
Trimble